

CÔNG TY CỔ PHẦN DƯỢC PHẨM  
HÀ TÂY

CỘNG HÒA XÃ HỘI CHỦ NGHĨA VIỆT NAM

Độc lập - Tự do - Hạnh phúc

Số: 409 /CV-DHT

Hà Nội, ngày 29 tháng 04 năm 2026

## CÔNG BỐ THÔNG TIN ĐỊNH KỲ BÁO CÁO TÀI CHÍNH

Kính gửi: Sở Giao dịch Chứng khoán Hà Nội

Thực hiện quy định tại Khoản 3 Điều 14 Thông tư số 96/2020/TT-BTC ngày 16/11/2020 của Bộ Tài chính hướng dẫn công bố thông tin trên thị trường chứng khoán, CTCP Dược phẩm Hà Tây thực hiện công bố thông tin báo cáo tài chính (BCTC) quý 1/năm 2026 với Sở Giao dịch Chứng khoán Hà Nội như sau:

1. Tên tổ chức: CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

- Mã chứng khoán: DHT
- Địa chỉ: Số 10A phố Quang Trung, phường Hà Đông, TP. Hà Nội
- Điện thoại liên hệ/Tel: 0433 501 117 Fax:
- Email: [duochatay@gmail.com](mailto:duochatay@gmail.com)
- Website: <https://www.hataphar.com.vn>

2. Nội dung thông tin công bố:

- BCTC quý 1/năm 2026

☒ BCTC riêng (TCNY không có công ty con và đơn vị kế toán cấp trên có đơn vị trực thuộc);

☒ BCTC hợp nhất (TCNY có công ty con);

☐ BCTC tổng hợp (TCNY có đơn vị kế toán trực thuộc tổ chức bộ máy kế toán riêng).

- Các trường hợp thuộc diện phải giải trình nguyên nhân:

+ Tổ chức kiểm toán đưa ra ý kiến không phải là ý kiến chấp nhận toàn phần đối với BCTC (đối với BCTC được soát xét/được kiểm toán):

☐ Có

☒ Không

Văn bản giải trình trong trường hợp tích có:

☐ Có

☐ Không

+ Lợi nhuận sau thuế trong kỳ báo cáo có sự chênh lệch trước và sau kiểm toán từ 5% trở lên, chuyển từ lỗ sang lãi hoặc ngược lại (đối với BCTC được kiểm toán năm 2026):

☐ Có

☒ Không





Văn bản giải trình trong trường hợp tích có:

☐ Có

☐ Không

+ Lợi nhuận sau thuế thu nhập doanh nghiệp tại báo cáo kết quả kinh doanh của kỳ báo cáo thay đổi từ 10% trở lên so với báo cáo cùng kỳ năm trước:

☒ Có

☐ Không

Văn bản giải trình trong trường hợp tích có:

☒ Có

☐ Không

+ Lợi nhuận sau thuế trong kỳ báo cáo bị lỗ, chuyển từ lãi ở báo cáo cùng kỳ năm trước sang lỗ ở kỳ này hoặc ngược lại:

☐ Có

☒ Không

Văn bản giải trình trong trường hợp tích có:

☐ Có

☐ Không

Thông tin này đã được công bố trên trang thông tin điện tử của công ty vào ngày: 29/04/2026 tại đường dẫn: <https://www.hataphar.com.vn/thong-tin-codong.html3>.

3. Báo cáo về các giao dịch có giá trị từ 35% tổng tài sản trở lên trong năm 2026: Không có

Trường hợp TCNY có giao dịch đề nghị báo cáo đầy đủ các nội dung sau:

- Nội dung giao dịch:
- Tỷ trọng giá trị giao dịch/tổng giá trị tài sản của doanh nghiệp (%) (căn cứ trên báo cáo tài chính năm gần nhất):
- Ngày hoàn thành giao dịch

Chúng tôi xin cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin công bố.

#### Đại diện tổ chức

Người đại diện theo pháp luật/Người UQCBTT  
(Ký, ghi rõ họ tên, chức vụ, đóng dấu)

#### Tài liệu đính kèm:

- BCTC riêng Quý 1.2026
- BCTC HN Quý 1.2026
- Văn bản giải trình



TỔNG GIÁM ĐỐC  
**OSAMU YOMOGIDA**



**HATAY PHARMACEUTICAL JOINT STOCK COMPANY**  
**CONSOLIDATED FINANCIAL STATEMENTS**

**For the period from 01/01/2026 to 31/03/2026**

---

**Ha Noi, April 2026**



No. 413 /CV-BCTC-DHT

**SOCIALIST REPUBLIC OF VIETNAM**  
**Independence - Freedom - Happiness**

*Hanoi, April 29, 2026*

**To: The State Securities Commission of Viet Nam**  
**Hanoi Stock Exchange**

Company name: Ha Tay Pharmaceutical Joint Stock Company

Stock Code: DHT

Head office: 10A Quang Trung – Ha Dong Ward – Hanoi City

Phone: 0433 501 117 – Fax: 0433 829 054

Information disclosure officer: Ms. Pham Minh Thu – Deputy Head of Legal and Communications Department.

In the consolidated financial statements for Q1 2026, the business results of Hatay Pharmaceutical Joint Stock Company are as follows:

The total profit after tax in Q1 2026 was VND 8,981,165,004, compared to VND 23,911,253,100 in Q1 2025 - a decrease of VND 14,930,088,096, equivalent to a drop of 62.43%. This was mainly due to:

- Gross profit from goods sold and services in Q1 2026 amounted to VND 38,787,757,298, compared to gross profit from goods sold and services Q1 2025 amounted to VND 56,226,306,304 - a decrease of VND 17,438,549,006, equivalent to a drop of 31.01%. This decline was due to a decrease in sales of our own products, which have higher gross profit margin.
- Selling and administrative expenses in Q1 2026 amounted to VND 36,413,777,361 compared to VND 39,570,563,421 in Q1 2025, a decrease of VND 3,156,786,060, equivalent to a drop of 7.97%.

We hereby report to the State Securities Commission of Vietnam and the Hanoi Stock Exchange for your information.

*Recipient:*

- As above
- Archive: Office files

**HA TAY PHARMACEUTICAL JOINT STOCK  
COMPANY**



**General Director**

*Osamu Yomogida*  
**Osamu Yomogida**



Form B 01 - DN/HN

**CONSOLIDATED BALANCE SHEET**

As at March 31, 2026

Unit: VND

ASSETS	Codes	Notes	31/03/2026	01/01/2026
<b>A - CURRENT ASSETS</b>	<b>100</b>		<b>737,774,408,197</b>	<b>896,739,416,323</b>
<b>I. Cash and cash equivalents</b>	<b>110</b>	<b>V.01</b>	<b>138,480,633,122</b>	<b>84,336,751,569</b>
1 Cash	111		128,180,633,122	74,036,751,569
2 Cash equivalents	112		10,300,000,000	10,300,000,000
<b>II. Short-term financial investments</b>	<b>120</b>		<b>60,000,000,000</b>	<b>150,000,000,000</b>
1 Held-to-maturity investments	123	V.02	60,000,000,000	150,000,000,000
<b>III. Short-term receivables</b>	<b>130</b>		<b>152,121,880,858</b>	<b>149,005,705,207</b>
1 Short-term trade receivables	131	V.03	111,565,356,387	111,636,095,800
2 Short-term advances to suppliers	132	V.04	42,800,484,782	37,840,076,173
3 Other short-term receivables	135	V.05	1,637,185,183	3,410,678,728
4 Provision for short-term doubtful debts	136	V.06	(3,881,145,494)	(3,881,145,494)
<b>IV. Inventories</b>	<b>140</b>	<b>V.07</b>	<b>387,171,894,217</b>	<b>513,396,959,547</b>
1 Inventories	141		387,171,894,217	513,396,959,547
2 Provision for devaluation of inventories	142		-	-
<b>B - NON-CURRENT ASSETS</b>	<b>200</b>		<b>1,038,392,654,054</b>	<b>1,035,177,856,096</b>
<b>I. Long-term receivables</b>	<b>210</b>	<b>V.05</b>	<b>6,407,042,500</b>	<b>6,407,042,500</b>
<b>II. Fixed assets</b>	<b>220</b>		<b>170,010,097,309</b>	<b>174,908,301,066</b>
1 Tangible fixed assets	221	V.08	168,633,437,309	173,531,641,066
Cost	222		442,891,416,571	446,492,048,355
Accumulated depreciation	223		(274,257,979,262)	(272,960,407,289)
2 Intangible fixed assets	227	V.09	1,376,660,000	1,376,660,000
Cost	228		2,026,660,000	2,026,660,000
Accumulated amortization	229		(650,000,000)	(650,000,000)
<b>III. Long-term assets in progress</b>	<b>250</b>		<b>835,857,158,120</b>	<b>827,184,318,661</b>
1 Construction in progress	252	V.10	835,857,158,120	827,184,318,661
<b>IV. Long-term financial investments</b>	<b>260</b>	<b>V.02</b>	<b>20,267,299,501</b>	<b>19,860,292,957</b>
1 Investment in joint-ventures, associates	262		20,267,299,501	19,860,292,957
<b>V. Other long-term assets</b>	<b>270</b>		<b>5,851,056,624</b>	<b>6,817,900,912</b>
1 Long-term prepayments expenses	271	V.11	5,175,041,151	5,632,174,250
2 Deferred tax assets	272	V.12	676,015,473	1,185,726,662
<b>TOTAL ASSETS (280=100+200)</b>	<b>280</b>		<b>1,776,167,062,251</b>	<b>1,931,917,272,419</b>

Form B 01 - DN/HN

CONSOLIDATED BALANCE SHEET

As at March 31, 2026  
(continued)

RESOURCES	Codes	Notes	31/03/2026	Unit: VND 01/01/2026
<b>C - LIABILITIES</b>	<b>300</b>		<b>656,231,290,549</b>	<b>820,716,628,095</b>
<b>I. Current liabilities</b>	<b>310</b>		<b>569,622,143,002</b>	<b>734,022,780,548</b>
1 Short - term trade payables	311	V.13	179,813,051,519	261,260,793,034
2 Short - term advances from customers	312	V.14	134,901,581,032	177,983,077,668
3 Taxes and amounts payable to the State budget	314	V.15	2,012,412,734	5,515,053,039
4 Payables to employees	315		20,593,132,476	28,051,603,241
5 Short-term accrued expenses	316	V.17	156,106,955	161,520,303
6 Short-term unearned revenue	319	V.18	4,819,527,670	6,418,086,306
7 Other current payables	320	V.19	1,446,683,841	783,924,677
8 Short-term loans and obligations under finance leases	321	V.16	224,550,826,703	249,995,403,408
9 Bonus and welfare funds	323		1,328,820,072	3,853,318,872
<b>II. Long-term liabilities</b>	<b>330</b>		<b>86,609,147,547</b>	<b>86,693,847,547</b>
1 Other long-term payables	338	V.19	3,540,900,000	3,625,600,000
2 Long-term loans and obligations under finance leases	339	V.16	83,068,247,547	83,068,247,547
<b>D - EQUITY</b>	<b>400</b>		<b>1,119,935,771,702</b>	<b>1,111,200,644,324</b>
1 Owner's contributed capital	411	V.20	905,755,510,000	905,755,510,000
- Ordinary shares carrying voting rights	411a		905,755,510,000	905,755,510,000
2 Share premium	412	V.20	37,282,220,000	37,282,220,000
3 Other owners' equity	414	V.20	2,236,413,529	26,612,306,630
4 Treasury shares	415	V.20	(8,083,874,357)	(8,083,874,357)
5 Investment and development fund	418	V.20	10,749,248,213	10,749,248,213
6 Retained earnings	420	V.20	143,533,364,716	110,355,967,042
- Retained earnings accumulated to the prior year end	420a		134,485,822,517	56,699,133,435
- Retained earnings of current year	420b		9,047,542,199	53,656,833,607
8 Non-controlling interest	429	V.20	28,462,889,601	28,529,266,796
<b>II. Other resources and funds</b>	<b>430</b>		<b>-</b>	<b>-</b>
<b>TOTAL RESOURCES (440=300+400)</b>	<b>440</b>		<b>1,776,167,062,251</b>	<b>1,931,917,272,419</b>

Hanoi, April 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by

Chief Accountant

General Director





Nguyen Thi Bich Ngoc

Dinh Nam Ha

Osamu Yomogida



**CONSOLIDATED INCOME STATEMENT**

For the period from 01/01/2026 to 31/03/2026

Unit: VND

Year 2025

Year 2026

Quarter I

Year 2025

Codes Notes

Year 2026

ITEMS

1	Gross revenue from goods sold and services rendered	01	VI.1	568,856,645,088	496,009,439,335	568,856,645,088	496,009,439,335
2	Deductions	02	VI.2	29,071,000	837,000	29,071,000	837,000
3	Net revenue from goods sold and services rendered (10=01-02)	10	VI.3	568,827,574,088	496,008,602,335	568,827,574,088	496,008,602,335
4	Cost of sales	11	VI.4	530,039,816,790	439,782,296,031	530,039,816,790	439,782,296,031
5	Gross profit from goods sold and services rendered (20=10-11)	20		38,787,757,298	56,226,306,304	38,787,757,298	56,226,306,304
6	Financial income	22	VI.5	7,546,552,477	10,612,161,237	7,546,552,477	10,612,161,237
7	Financial expenses	23	VI.6	3,136,905,723	3,798,573,962	3,136,905,723	3,798,573,962
	In which: Interest expense	24		2,878,368,696	3,696,928,335	2,878,368,696	3,696,928,335
8	Selling expenses	25	VI.9	12,509,770,739	7,284,655,731	12,509,770,739	7,284,655,731
9	General and administration expenses	26	VI.9	23,904,006,622	32,285,907,690	23,904,006,622	32,285,907,690
10	Profit or loss from associates, joint ventures	27		653,044,170	2,833,064,521	653,044,170	2,833,064,521
11	Operating profit	30		7,436,670,861	26,302,394,679	7,436,670,861	26,302,394,679
	{30 = 20 + (22 - 23) - (25 + 26)+27}						
12	Other income	31	VI.7	3,640,556,691	3,662,469,912	3,640,556,691	3,662,469,912
13	Other expenses	32	VI.8	3,920,424	629,180,244	3,920,424	629,180,244
14	Profit from other activities (40=31-32)	40		3,636,636,267	3,033,289,668	3,636,636,267	3,033,289,668
15	Accounting profit before tax (50=30+ 40)	50		11,073,307,128	29,335,684,347	11,073,307,128	29,335,684,347
16	Current CIT expense	51	VI.10	1,582,430,935	5,424,431,247	1,582,430,935	5,424,431,247

17	Deferred CIT expense	52	VL.11	509,711,189	-	509,711,189	-
18	Net profit after corporate income tax (60=50-51-52)	60		8,981,165,004	23,911,253,100	8,981,165,004	23,911,253,100
19	The Parent company's net profit after tax	61		9,047,542,199	21,300,846,270	9,047,542,199	21,300,846,270
20	The non-controlling interests shareholders' net profit after tax	62		(66,377,195)	2,610,406,830	(66,377,195)	2,610,406,830

Hanoi, April 28, 2026

# HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by



Nguyen Thi Bich Ngoc

Chief Accountant



Dinh Nam Ha

General Director



Osamu Yomogida



## CONSOLIDATED CASH FLOWS STATEMENT

(Under indirect method)

For the period from 01/01/2026 to 31/03/2026

Unit: VND  
Year 2025

ITEMS	Code s	Notes	Quarter I		Year 2026	Year 2025
			Year 2026	Year 2025		
<b>I. Cash flow from operating activities</b>						
1. Profit before tax	01		11,073,307,128	29,335,684,347	11,073,307,128	29,335,684,347
2. Adjustments for						
- Depreciation of fixed assets and investment properties	02		6,189,329,757	5,665,753,893	6,189,329,757	5,665,753,893
- Gain, loss from investing activities	05		(2,410,454,324)	(9,161,754,128)	(2,410,454,324)	(9,161,754,128)
- Interest expense	06		2,878,368,696	3,696,928,335	2,878,368,696	3,696,928,335
3. Profit from operating activities before changes in working capital	08		17,730,551,257	29,536,612,447	17,730,551,257	29,536,612,447
- Increases, Decreases in receivables	09		(603,016,682)	71,430,878,347	(603,016,682)	71,430,878,347
- Increases, Decreases in inventories	10		126,225,065,330	(24,721,855,979)	126,225,065,330	(24,721,855,979)
- Increases, Decreases in payables (excluding interest payable, corporate income tax payable)	11		(139,658,814,263)	(2,640,423,266)	(139,658,814,263)	(2,640,423,266)
- Increases, Decreases in prepayment expense	12		457,133,099	44,508,039	457,133,099	44,508,039
- Interest expense paid	14		2,722,261,741	(4,670,830,867)	2,722,261,741	(4,670,830,867)
- Corporate income tax paid	15		(4,550,220,339)	(5,070,076,715)	(4,550,220,339)	(5,070,076,715)
- Other cash outflows	17		(2,770,536,426)	(1,300,000)	(2,770,536,426)	(1,300,000)
Net cash flow from operating activities	20		(447,576,283)	63,907,512,006	(447,576,283)	63,907,512,006
<b>II. Cash flow from investing activities</b>						
1. Acquisition and construction of fixed assets and other non-current assets	21		(9,963,965,459)	(21,141,969,949)	(9,963,965,459)	(21,141,969,949)
2. Proceeds from liquidation, disposal of fixed assets and other non-current assets	22		-	50,000,000	-	50,000,000
3. Cash outflows for lending, buying debt instruments of other entities	23		-	(180,000,000,000)	-	(180,000,000,000)

4. Cash recovered from lending, selling debt instruments of other entities	24	90,000,000,000	133,287,565,579	90,000,000,000	133,287,565,579
5. Interest earned, dividends and profits received	27	-	8,422,990,978	-	8,422,990,978
<i>Net cash flow from investing activities</i>	30	80,036,034,541	(59,381,413,392)	80,036,034,541	(59,381,413,392)

### III. Cash flow from financial activities

1. Proceeds from share issue and owners' contributed capital	31	-	-	-	-
2. Proceeds from borrowing	33	143,262,282,349	159,930,914,200	143,262,282,349	159,930,914,200
3. Repayment of borrowing	34	(168,706,859,054)	(190,953,113,452)	(168,706,859,054)	(190,953,113,452)
4. Dividends and profit paid to owners	36	-	-	-	-
<i>Net cash flow from financial activities</i>	40	(25,444,576,705)	(31,022,199,252)	(25,444,576,705)	(31,022,199,252)
<b>Net cash flow in the period (50 = 20+30+40)</b>	50	54,143,881,553	(26,496,100,638)	54,143,881,553	(26,496,100,638)
<b>Cash and cash equivalents at the beginning of the period</b>	60	84,336,751,569	90,269,672,873	84,336,751,569	90,269,672,873
Effect of changes in foreign exchange rates	61	-	-	-	-
<b>Cash and cash equivalents at the end of the period</b>	70	138,480,633,122	63,773,572,235	138,480,633,122	63,773,572,235
	V.01				

Hanoi, April 28, 2026

### HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Chief Accountant

General Director



*(Signature)*

Nguyen Thi Bich Ngoc

Dinh Nam Ha

Osamu Yomogida



Form B 09 - DN/HN

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

**V. Additional information of items presented in the Consolidated Balance Sheet**

**1. Cash and cash equivalents**

	31/03/2026	01/01/2026
	VND	VND
<b>Cash</b>	<b>128,180,633,122</b>	<b>74,036,751,569</b>
<i>Cash on hand</i>	<i>5,332,380,316</i>	<i>5,265,522,207</i>
<i>Cash in bank</i>	<i>122,848,252,806</i>	<i>68,771,229,362</i>
VND	122,416,440,680	68,646,493,402
USD	421,208,209	113,685,066
EUR	10,603,917	11,050,894
<b>Cash equivalents (*)</b>	<b>10,300,000,000</b>	<b>10,300,000,000</b>
Bank deposits with terms of less than 3 months	10,300,000,000	10,300,000,000
<b>Total</b>	<b>138,480,633,122</b>	<b>84,336,751,569</b>

**2. Financial investments**

**a) Held-to-maturity investments**

	31/03/2026		01/01/2026	
	VND		VND	
	Cost	Carrying amount	Cost	Carrying amount
<b>Short-term</b>	<b>60,000,000,000</b>	<b>60,000,000,000</b>	<b>150,000,000,000</b>	<b>150,000,000,000</b>
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch	-	-	80,000,000,000	80,000,000,000
Viet A Commercial Joint Stock Bank - Ha Dong Branch	40,000,000,000	40,000,000,000	30,000,000,000	30,000,000,000
Vietnam Technological and Commercial Joint Stock Bank - Dong Do Branch	20,000,000,000	20,000,000,000	40,000,000,000	40,000,000,000
<b>Total</b>	<b>60,000,000,000</b>	<b>60,000,000,000</b>	<b>150,000,000,000</b>	<b>150,000,000,000</b>

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)***(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)***b) Investment in other entities**

	31/03/2026		01/01/2026	
	VND		VND	
	Cost	Adjustment in the year	Book value	Cost
				Adjustment in the year
				Book value
<i>Investment in associates</i>				
Southern Hataphar Company Limited (i)	700,000,000	194,045,742	894,045,742	700,000,000
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC (ii)	2,450,000,000	16,923,253,759	19,373,253,759	2,450,000,000
<b>Total</b>	<b>3,150,000,000</b>	<b>17,117,299,501</b>	<b>20,267,299,501</b>	<b>3,150,000,000</b>
				<b>16,710,292,957</b>
				<b>19,860,292,957</b>

**- Summary of the operations of the associated companies during the period:**

(i) Under the 7th amended Business Registration Certificate dated June 15, 2017 issued by the Department of Planning and Investment of Ho Chi Minh City, the Company invested VND 700,000,000 in Southern Hataphar Company Limited, equivalent to 48.28% of the charter capital. At the end of the period, the Company invested VND 700,000,000, equivalent to 48.28% of the charter capital.

(ii) During the year, Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC issued dividends in the form of shares, increasing 490,000 shares held by the Company in this affiliate. By the end of the fiscal year, the Company owned 49% of the charter capital, which amounts to a total of 980,000 shares. According to the 3rd amended Business Registration Certificate dated June 11, 2025, the Company invested in Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company with a value of VND 9,800,000,000,

The associated companies are functioning normally, with no significant changes compared to the previous year.

As at March 31, 2026, it has not been possible to determine the fair value of the investments mentioned above due to a lack of market prices or insufficient information needed for assessment. The fair value of these investments may differ from their book value.



Form B 09 - DN/HN

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

**3. Trade receivable**

	31/03/2026		01/01/2026	
	VND		VND	
	Amount	Provision	Amount	Provision
<b>Short-term</b>	<b>111,565,356,387</b>	<b>(3,881,145,494)</b>	<b>111,636,095,800</b>	<b>(3,881,145,494)</b>
<i>- Some large balances in trade receivables:</i>				
Thanh Vinh Pharmaceutical and Medical Materials JSC	642,494,550	-	148,639,650	-
Thuan Anh Pharmaceutical Company Limited	1,063,740,258	-	5,779,512,102	-
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	12,008,124,924	-	40,103,925,920	-
Phap Au Pharmaceutical JSC	1,354,024,131	-	892,019,757	-
Duc Tam Company Limited	3,030,340,447	-	2,739,541,083	-
Vinh Gia Pharmaceutical JSC	3,448,431,871	-	1,064,753,077	-
Truong Huy Company Limited	1,998,999,118	-	2,969,374,918	-
Vinaplant Pharmaceutical	7,680,325,296	-	6,973,025,318	-
Stabled Pharmaceutical Company Limited	2,819,008,080	-	884,881,615	-
Kim Long Investment JSC	1,694,750,311	-	1,657,733,296	-
Thu Duc City Hospital	7,871,170,800	(1,671,860,000)	1,774,525,000	(1,671,860,000)
T&T Equipment Joint Stock Company	7,871,170,800	-	9,799,671,420	-
Quang Cường Pharmaceutical Joint Stock Company	65,106,130	-	8,019,153,310	-

**4. Advances to suppliers**

	31/03/2026	01/01/2026
	VND	VND
<b>Short-term</b>	<b>42,800,484,782</b>	<b>37,840,076,173</b>
<i>- Some large balances in Advances to suppliers:</i>		
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	-	1,830,521,186
DHG Pharmaceutical Joint Stock Company	1,283,604,000	-
Pharmametics products a division of max Biocare	8,385,497,006	2,573,704,006
Delta Pharma Ltd	15,253,609,956	7,846,059,364
Inbiotech l.t.d	-	6,997,520,425
Saifen Drugs Philippines Inc	4,976,837,628	2,840,549,628
Bliss pharma distribution and Consultancy corp	2,706,305,880	3,384,715,680

Form B 09 - DN/HN

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

5. Other receivables	31/03/2026		01/01/2026	
	VND		VND	
	Amount	Provision	Amount	Provision
a) Short - term	8,044,227,683	-	9,817,721,228	
Other receivables	1,249,208,872	-	3,279,702,417	-
Estimated interest receivable	1,037,369,870	-	3,116,239,427	-
Others	211,839,002	-	163,462,990	-
Advances	387,976,311	-	130,976,311	-
Nguyễn Văn Phúc	100,000,000	-	-	-
Trần Thị Phương Anh	59,000,000	-	-	-
Others	228,976,311	-	130,976,311	-
b) Long - term				
Mortgages, deposits	6,407,042,500	-	6,407,042,500	-
Management Board of Hoa Lac High-Tech Park	6,407,042,500	-	6,407,042,500	-
<b>Total</b>	<b>8,044,227,683</b>	<b>-</b>	<b>9,817,721,228</b>	<b>-</b>
6. Bad debts	31/03/2026		01/01/2026	
	VND		VND	
	Cost	Recoverable amount	Cost	Recoverable amount
Total value of receivables, that are overdue and difficult to recover				
Accounts receivable				
Thu Duc City Hospital	1,774,525,000	102,665,000	1,774,525,000	102,665,000
Others	1,765,357,618	267,744,124	1,765,357,618	267,744,124
Advances to suppliers				
ERP Solutions Joint Stock Company	711,672,000	-	711,672,000	-
<b>Total</b>	<b>4,251,554,618</b>	<b>370,409,124</b>	<b>4,251,554,618</b>	<b>370,409,124</b>
7. Inventories	31/03/2026		01/01/2026	
	VND		VND	
	Cost	Provision	Cost	Provision
Purchased goods in transit	64,748,772,530	-	127,357,336,205	-
Raw materials	71,802,755,283	-	74,584,107,934	-
Tools and supplies	347,317,770	-	342,444,153	-
Work in progress	11,624,484,158	-	9,735,832,625	-
Finished goods	33,892,128,519	-	23,437,595,070	-
Goods	204,756,435,957	-	277,939,643,560	-
<b>Total</b>	<b>387,171,894,217</b>	<b>-</b>	<b>513,396,959,547</b>	<b>-</b>



**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**

*(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)*

8. Increases, decreases in tangible fixed assets						Unit: VND
Items	Building and structures	Machinery, equipment	Means of transport, transmission equipment	Office equipment and tools	Other fixed assets	Total
<b>Cost</b>						
Balance as at 01/01/2026	168,479,750,526	259,070,786,133	14,109,417,253	4,392,811,943	439,282,500	446,492,048,355
Purchase in the year	-	1,152,439,000	-	138,687,000	-	1,291,126,000
Construction completed	-	-	-	-	-	-
Liquidation of fixed assets	-	(4,891,757,784)	-	-	-	(4,891,757,784)
Balance as at 31/03/2026	168,479,750,526	255,331,467,349	14,109,417,253	4,531,498,943	439,282,500	442,891,416,571
<b>Accumulated depreciation</b>						
Balance as at 01/01/2026	101,863,548,984	159,551,744,355	7,193,456,388	3,912,375,062	439,282,500	272,960,407,289
Depreciation in the year	1,826,478,483	4,078,846,740	248,227,074	35,777,460	-	6,189,329,757
Liquidation of fixed assets	-	(4,891,757,784)	-	-	-	(4,891,757,784)
Balance as at 31/03/2026	103,690,027,467	158,738,833,311	7,441,683,462	3,948,152,522	439,282,500	274,257,979,262
<b>Net book value</b>						
As at 01/01/2026	66,616,201,542	99,519,041,778	6,915,960,865	480,436,881	-	173,531,641,066
As at 31/03/2026	64,789,723,059	96,592,634,038	6,667,733,791	583,346,421	-	168,633,437,309

Form B 09 - DN/HN

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

**9. Increases, decreases in intangible fixed assets**

Items	Unit: VND		
	Accounting	Land use rights	Total
<b>Cost</b>			
Balance as at 01/01/2026	650,000,000	1,376,660,000	2,026,660,000
Purchase in the year	-	-	-
Balance as at 31/03/2026	650,000,000	1,376,660,000	2,026,660,000
<b>Accumulated amortization</b>			
Balance as at 01/01/2026	650,000,000	-	650,000,000
Amortization in the year	-	-	-
Balance as at 31/03/2026	650,000,000	-	650,000,000
<b>Net book value</b>			
As at 01/01/2026	-	1,376,660,000	1,376,660,000
As at 31/03/2026	-	1,376,660,000	1,376,660,000

**10. Construction in progress**

	31/03/2026	01/01/2026
	VND	VND
Hataphar High-Tech Pharmaceutical Factory	812,143,633,217	807,746,227,200
Bioequivalent cost	1,629,629,630	1,277,777,778
Purchasing fixed assets	-	925,925,926
Factory Renovation	-	2,674,508,863
Cost of research and development of pharmaceutical products	22,083,895,273	14,559,878,894
<b>Total</b>	<b>835,857,158,120</b>	<b>827,184,318,661</b>

**11. Prepayments**

	31/03/2026	01/01/2026
	VND	VND
<b>Long-term</b>		
Issued tools and instruments awaiting for allocation	1,569,514,051	2,465,920,534
Repair and renovation costs	3,218,579,883	2,858,499,091
Other Prepayments	386,947,217	307,754,625
<b>Total</b>	<b>5,175,041,151</b>	<b>5,632,174,250</b>

**12. Deferred tax assets**

	31/03/2026	01/01/2026
	VND	VND
Corporate income tax rates are used to determine the value of deferred income tax assets.	20%	20%
Deferred income tax assets relate to deductible temporary differences.	676,015,473	1,185,726,662
<b>Total</b>	<b>676,015,473</b>	<b>1,185,726,662</b>



Form B 09 - DN/HN

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

**13 Trade payables**

	31/03/2026		01/01/2026	
	VND		VND	
	Amount	Amount able to be paid off	Amount	Amount able to be paid off
<b>Short - term</b>	<b>179,813,051,519</b>	<b>179,813,051,519</b>	<b>261,260,793,034</b>	<b>261,260,793,034</b>
<i>- Some large balances in Trade payables:</i>				
Dong Au Trading and Production Company Limited	248,473,649	248,473,649	3,907,753,067	3,907,753,067
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	4,240,904,962	4,240,904,962	11,392,041,392	11,392,041,392
KPC Pharmaceuticals, Inc	-	-	19,025,983,320	19,025,983,320
XL Laboratories PVT.,LTD	13,248,407,776	13,248,407,776	22,359,757,441	22,359,757,441
Pharmaunity Co.,Ltd	13,283,716,937	13,283,716,937	13,349,510,483	13,349,510,483
Delta Pharma Ltd	44,929,918,624	44,929,918,624	35,828,249,950	35,828,249,950
Blis pharma distribution and Consultancy corp	16,312,886,913	16,312,886,913	40,758,864,060	40,758,864,060
Pharmametics products a division of Max Biocare	13,283,716,937	13,283,716,937	13,799,528,479	13,799,528,479
HK Inno.n Corporation	7,227,919,858	7,227,919,858	8,187,209,784	8,187,209,784

**14 Advances from customers**

	31/03/2026	01/01/2026
	VND	VND
<b>Short - term</b>	<b>134,901,581,032</b>	<b>177,983,077,668</b>
<i>- Some large balances in Advances from customers:</i>		
T&T Equipment Joint Stock Company	1,085,416,000	6,442,145,755
Thuan An Phat Pharmaceutical Joint Stock Company	683,800,000	10,784,000,000
Dong Do Pharmaceutical Company Limited	6,031,762,463	2,502,291,750
TB Vietnam Pharmaceutical Trading Company Limited	50,784,685,345	49,761,555,583
Bach Gia Pharmaceutical Company Limited	3,503,987,950	7,276,190,274
Hieu Anh Pharmaceutical Company Limited	12,269,259,000	8,045,259,000
Lam An Pharmaceutical Trading Company Limited	-	6,509,000,000
1A Vietnam Pharmaceutical Company Limited	5,956,000,000	4,658,505,656
Dai Song Duong Biopharmaceutical Company Limited	2,146,447,581	9,028,478,251
California USA Pharmaceutical Company Limited	12,114,963,007	5,753,424,645
French Pharmaceutical Joint Stock Company	1,129,794,332	28,976,548,644

**Form B 09 - DN/HN**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**

*(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)*

**15 Taxes and amounts payable to the State budget**

Unit: VND

Items	01/01/2026	Payable during the year	Paid during the year	31/03/2026
<b>Payables</b>				
Output value added tax	841,144,007	3,662,514,004	4,149,620,598	354,037,413
Value added tax on imports	-	-	-	-
Corporate income tax	4,550,220,339	1,582,430,935	4,550,220,339	1,582,430,935
Personal income tax	123,688,693	2,230,440,593	2,278,184,900	75,944,386
<b>Total</b>	<b>5,515,053,039</b>	<b>7,475,385,532</b>	<b>10,978,025,837</b>	<b>2,012,412,734</b>



**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**

**Form B 09 - DN/HN**

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

**15. Loans and obligations under finance lease**

**Loans**

Unit: VND

	31/03/2026		In the year		01/01/2026	
	Amount	Amount able to be paid off	Increases	Decreases	Amount	Amount able to be paid off
<b>a) Short-term</b>	<b>224,550,826,703</b>	<b>224,550,826,703</b>	<b>143,262,282,349</b>	<b>168,706,859,054</b>	<b>249,995,403,408</b>	<b>249,995,403,408</b>
<i>Short-term loans</i>	<i>210,706,118,778</i>	<i>210,706,118,778</i>	<i>143,262,282,349</i>	<i>168,706,859,054</i>	<i>236,150,695,483</i>	<i>236,150,695,483</i>
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch	16,817,521,723	16,817,521,723	14,385,327,931	28,063,622,057	30,495,815,849	30,495,815,849
Joint Stock Commercial Bank for Foreign Trade of Vietnam - Ha Tay Branch	31,017,903,411	31,017,903,411	16,999,158,361	48,293,866,909	62,312,611,959	62,312,611,959
Shinhan Bank Limited - Hanoi Branch	79,103,477,913	79,103,477,913	56,341,044,576	29,288,427,652	52,050,860,989	52,050,860,989
Joint Stock Commercial Bank for Investment and Development of Vietnam - Ngoc Khanh Branch	37,398,770,677	37,398,770,677	37,398,770,677	24,409,904,245	24,409,904,245	24,409,904,245
Personal loans	24,809,109,510	24,809,109,510	7,357,413,229	28,596,455,291	46,048,151,572	46,048,151,572
<i>Long-term loans on due date</i>	<i>13,844,707,925</i>	<i>13,844,707,925</i>	-	-	<i>13,844,707,925</i>	<i>13,844,707,925</i>
MUFG Bank, LTD - Hanoi Branch	13,844,707,925	13,844,707,925	-	-	13,844,707,925	13,844,707,925
<b>b) Long-term loans</b>	<b>83,068,247,547</b>	<b>83,068,247,547</b>	-	-	<b>83,068,247,547</b>	<b>83,068,247,547</b>
MUFG Bank, LTD - Hanoi Branch	83,068,247,547	83,068,247,547	-	-	83,068,247,547	83,068,247,547
<b>Total</b>	<b>307,619,074,250</b>	<b>307,619,074,250</b>	<b>143,262,282,349</b>	<b>168,706,859,054</b>	<b>333,063,650,955</b>	<b>333,063,650,955</b>

Form B 09 - DN/HN

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**

*(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)*

17	Accrued expenses	31/03/2026	01/01/2026
		VND	VND
	<b>Short-term</b>		
	Accrued interest expense	156,106,955	161,520,303
	<b>Total</b>	<b>156,106,955</b>	<b>161,520,303</b>
18	Unearned revenue	31/03/2026	01/01/2026
		VND	VND
	<b>Short-term</b>		
	Unearned revenue from leases	1,453,216,384	575,370,229
	Unearned revenue corresponding to the inventory of external sales of the Associate Company in internal sales transactions.	3,366,311,286	5,842,716,077
	<b>Total</b>	<b>4,819,527,670</b>	<b>6,418,086,306</b>
19	Other payables	31/03/2026	01/01/2026
		VND	VND
a)	<b>Short-term</b>	<b>1,446,683,841</b>	<b>783,924,677</b>
	Insurance	698,527,488	592,397,733
	Other payables	748,156,353	191,526,944
b)	<b>Long-term</b>	<b>3,540,900,000</b>	<b>3,625,600,000</b>
	Long-term collaterals, deposits received	3,540,900,000	3,625,600,000
	<b>Total</b>	<b>4,987,583,841</b>	<b>4,409,524,677</b>



**HATAY PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No.10A Quang Trung Street, Ha Dong Ward, Hanoi City

**CONSOLIDATED FINANCIAL STATEMENTS**

For the period from 01/01/2026 to 31/03/2026

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**

**Form B 09 - DN/HN**

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

**20. Owner's equity**

**20.1 Movement in owner's equity**

Unit: VND

Items	Owner's contributed capital	Share premium	Other owners' equity	Treasury shares	Investment and development fund	Retained earnings	Non-controlling interest	Total
<b>Balance as at 01/01/2025</b>	<b>823,417,730,000</b>	<b>97,320,000,000</b>	<b>26,612,306,630</b>	<b>(8,083,874,357)</b>	<b>10,749,248,213</b>	<b>79,530,817,489</b>	<b>27,214,093,742</b>	<b>1,056,760,321,717</b>
Increase Owner's contributed capital from Share premium	60,037,780,000	(60,037,780,000)	-	-	-	-	-	-
Increase Owner's contributed capital from Other owners' equity	22,300,000,000	-	-	-	-	(22,300,000,000)	-	-
Profit in previous year	-	-	-	-	-	53,656,833,607	5,383,623,054	59,040,456,661
Decrease due to dividend distribution	-	-	-	-	-	-	(4,068,450,000)	(4,068,450,000)
Other decreases	-	-	-	-	-	(531,684,054)	-	(531,684,054)
<b>Balance as at 31/12/2025</b>	<b>905,755,510,000</b>	<b>37,282,220,000</b>	<b>26,612,306,630</b>	<b>(8,083,874,357)</b>	<b>10,749,248,213</b>	<b>110,355,967,042</b>	<b>28,529,266,796</b>	<b>1,111,200,644,324</b>
Profit/Loss in this year	-	-	-	-	-	9,047,542,199	(66,377,195)	8,981,165,004
Transfer of Other Capital to Retained earnings accumulated to the prior year end (*)	-	-	(24,375,893,101)	-	-	24,375,893,101	-	-
Other decreases	-	-	-	-	-	(246,037,626)	-	(246,037,626)
<b>Balance as at 31/03/2026</b>	<b>905,755,510,000</b>	<b>37,282,220,000</b>	<b>2,236,413,529</b>	<b>(8,083,874,357)</b>	<b>10,749,248,213</b>	<b>143,533,364,716</b>	<b>28,462,889,601</b>	<b>1,119,935,771,702</b>

(\*) Resolution No. 219/NQ-DHT dated March 30, 2026 of the General Meeting of Shareholders approving the audited financial statements for 2025 of the Board of Directors, which includes the transfer of all "Other capital of the owner" to "Undistributed after-tax profit" in the 2026 financial statements.

Form B 09 - DN/HN

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

### 20.2 Details of owner's equity contribution

	31/03/2026	01/01/2026
	VND	VND
Hanoi Investment Fund for Development	34,076,520,000	34,076,520,000
ASKA Pharmaceutical Co., Ltd	362,727,620,000	362,727,620,000
Le Van Lo	50,819,900,000	50,819,900,000
Ngo Van Chinh	22,195,920,000	22,195,920,000
Hoang Van Tue	36,153,210,000	36,153,210,000
Le Viet Linh	57,441,840,000	57,441,840,000
Le Anh Trung	33,718,720,000	33,718,720,000
Le Xuan Thang	35,205,290,000	35,205,290,000
Ngo Tuan Viet	5,500,000,000	5,500,000,000
Others	266,191,390,000	266,191,390,000
<b>Total</b>	<b>905,755,510,000</b>	<b>905,755,510,000</b>

### 20.3 Capital transactions with owners, dividend distribution and shared profit

	Year 2026	Year 2025
	VND	VND
<b>Owners' contributed capital</b>		
Contributed at current period's opening balance	905,755,510,000	823,417,730,000
Contributed capital increase during the year	-	-
Contributed at current period's closing balance	905,755,510,000	823,417,730,000
<b>Paid dividend, shared profit</b>	-	-

### 20.4 Shares

	31/03/2026	01/01/2026
	Shares	Shares
Number of shares registered for issue	90,575,551	82,341,773
Number of shares issued to the public	90,575,551	90,575,551
- Ordinary shares	90,575,551	90,575,551
- Preferred shares	-	-
Number of shares bought back	1,513	1,513
- Ordinary shares	1,513	1,513
- Preferred shares	-	-
Number of outstanding shares in circulation	90,574,038	90,574,038
- Ordinary shares	90,574,038	90,574,038
- Preferred shares	-	-
Par value of outstanding shares: VND 10,000/share		

### 20.5 Dividends

Dividends declared after the end of the accounting period:

- Dividends declared on ordinary shares: no

- Dividends declared on preferred shares: no

Unrecorded cumulative preferred shares dividends: no



Form B 09 - DN/HN

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS** (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

**20.6 Funds of the Company**

Unit: VND

Items	01/01/2026	Increase	Decrease	31/03/2026
Investment and development fund	10,749,248,213	-	-	10,749,248,213
<b>Total</b>	<b>10,749,248,213</b>	<b>-</b>	<b>-</b>	<b>10,749,248,213</b>

**21 Off Consolidated Balance Sheet items**

	31/03/2026	01/01/2026
<i>Foreign currencies</i>		
USD	16,220.29	4,387.44
EUR	357.55	365.98

**VI. Additional information for items presented in the Consolidated Income Statement**

**1. Gross revenue from goods sold and services rendered**

	Quarter I/2026 VND	Quarter I/2025 VND
Revenue from sales of finished products	111,410,951,101	166,690,364,602
Revenue from sales of goods	457,445,693,987	329,319,074,733
<b>Total</b>	<b>568,856,645,088</b>	<b>496,009,439,335</b>

**2. Revenue deductions**

	Quarter I/2026 VND	Quarter I/2025 VND
Sales returns	29,071,000	837,000
<b>Total</b>	<b>29,071,000</b>	<b>837,000</b>

**3. Net revenue from goods sold and services rendered**

	Quarter I/2026 VND	Quarter I/2025 VND
Net revenue from sales of finished products	111,381,880,101	166,689,527,602
Net revenue from sales of goods	457,445,693,987	329,319,074,733
<b>Total</b>	<b>568,827,574,088</b>	<b>496,008,602,335</b>

**4. Cost of sales**

	Quarter I/2026 VND	Quarter I/2025 VND
Cost of finished products sales	82,473,286,052	118,593,809,809
Cost of goods sales	447,566,530,738	321,188,486,222
<b>Total</b>	<b>530,039,816,790</b>	<b>439,782,296,031</b>

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)**

*(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)*

**5. Financial income**

	Quarter I/2026 VND	Quarter I/2025 VND
Financial income	7,546,552,477	10,612,161,237
<b>Total</b>	<b>7,546,552,477</b>	<b>10,612,161,237</b>

**6. Financial expenses**

	Quarter I/2026 VND	Quarter I/2025 VND
Financial expenses	3,136,905,723	3,798,573,962
<b>Total</b>	<b>3,136,905,723</b>	<b>3,798,573,962</b>

**7. Other income**

	Quarter I/2026 VND	Quarter I/2025 VND
Other income	3,640,556,691	3,662,469,912
<b>Total</b>	<b>3,640,556,691</b>	<b>3,662,469,912</b>

**8. Other expenses**

	Quarter I/2026 VND	Quarter I/2025 VND
Other expenses	3,920,424	629,180,244
<b>Total</b>	<b>3,920,424</b>	<b>629,180,244</b>

**9. Selling expenses and general and administration expenses**

	Quarter I/2026 VND	Quarter I/2025 VND
a) Selling expenses incurred in the period	12,509,770,739	7,284,655,731
b) General administration expenses incurred in the period	23,904,006,622	32,285,907,690
<b>Total</b>	<b>36,413,777,361</b>	<b>39,570,563,421</b>

**10. Current corporate income tax expense**

	Quarter I/2026 VND	Quarter I/2025 VND
Corporate income tax expense calculated on current taxable income	1,582,430,935	5,424,431,247
Adjustment of Corporate income tax expense in prior years into current Corporate income tax this year	-	-
<b>Total current corporate income tax expense</b>	<b>1,582,430,935</b>	<b>5,424,431,247</b>



Form B 09 - DN/HN

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS** *(continued)*

*(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)*

**11 Deferred corporate income tax expense**

	Quarter I/2026	Quarter I/2025
	VND	VND
Deferred corporate income tax expense arising from taxable temporary differences.	509,711,189	-
<b>Total</b>	<b>509,711,189</b>	<b>-</b>

Hanoi, April 28, 2026

**HATAY PHARMACEUTICAL JOINT STOCK COMPANY**

**Prepared by**



**Nguyen Thi Bich Ngoc**

**Chief Accountant**



**Dinh Nam Ha**

**General Director**



**Osamu Yomogida**